TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-000403
Abstract: Background FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed… read more here.
Keywords: metastatic colorectal; braf wild; colorectal cancer; plus panitumumab ... See more keywords
Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.12007
Abstract: 12007Background: CRICKET (NCT02296203) was designed to investigate the activity of the rechallenge with cet and iri as 3rd-line treatment in RAS/BRAF wild-type mCRC pts with acquired resistance to ... read more here.
Keywords: braf wild; pts acquired; cet; ras braf ... See more keywords
Hashimoto’s Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15082371
Abstract: Simple Summary Hashimoto’s thyroiditis and BRAF-mutation are protective and risk factors for thyroid cancer aggressiveness, respectively. We assessed the influence of Hashimoto’s thyroiditis and its influence on recurrence in patients with BRAF-wild type and BRAF-mutant… read more here.
Keywords: braf; protective factor; recurrence; braf wild ... See more keywords